Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 151

1.

Combining Tumor Microenvironment Modulating Nanoparticles with Doxorubicin to Enhance Chemotherapeutic Efficacy and Boost Antitumor Immunity.

Amini MA, Abbasi AZ, Cai P, Lip H, Gordijo CR, Li J, Chen B, Zhang L, Rauth AM, Wu XY.

J Natl Cancer Inst. 2018 Sep 14. doi: 10.1093/jnci/djy131. [Epub ahead of print]

PMID:
30239773
2.

Importance of integrating nanotechnology with pharmacology and physiology for innovative drug delivery and therapy - an illustration with firsthand examples.

Zhang RX, Li J, Zhang T, Amini MA, He C, Lu B, Ahmed T, Lip H, Rauth AM, Wu XY.

Acta Pharmacol Sin. 2018 May;39(5):825-844. doi: 10.1038/aps.2018.33. Epub 2018 Apr 26. Review.

PMID:
29698389
3.

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice.

Zhang RX, Zhang T, Chen K, Cheng J, Lai P, Rauth AM, Pang KS, Wu XY.

J Vis Exp. 2017 Oct 5;(128). doi: 10.3791/56159.

PMID:
29053672
4.

Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in mice.

Zhang T, Prasad P, Cai P, He C, Shan D, Rauth AM, Wu XY.

Acta Pharmacol Sin. 2017 Jun;38(6):835-847. doi: 10.1038/aps.2016.166. Epub 2017 Feb 20.

5.

Blood-brain barrier-penetrating amphiphilic polymer nanoparticles deliver docetaxel for the treatment of brain metastases of triple negative breast cancer.

He C, Cai P, Li J, Zhang T, Lin L, Abbasi AZ, Henderson JT, Rauth AM, Wu XY.

J Control Release. 2017 Jan 28;246:98-109. doi: 10.1016/j.jconrel.2016.12.019. Epub 2016 Dec 23.

PMID:
28017889
6.

Hybrid Manganese Dioxide Nanoparticles Potentiate Radiation Therapy by Modulating Tumor Hypoxia.

Abbasi AZ, Gordijo CR, Amini MA, Maeda A, Rauth AM, DaCosta RS, Wu XY.

Cancer Res. 2016 Nov 15;76(22):6643-6656. doi: 10.1158/0008-5472.CAN-15-3475. Epub 2016 Oct 6.

7.

Polymer-lipid hybrid nanoparticles synchronize pharmacokinetics of co-encapsulated doxorubicin-mitomycin C and enable their spatiotemporal co-delivery and local bioavailability in breast tumor.

Zhang RX, Cai P, Zhang T, Chen K, Li J, Cheng J, Pang KS, Adissu HA, Rauth AM, Wu XY.

Nanomedicine. 2016 Jul;12(5):1279-90. doi: 10.1016/j.nano.2015.12.383. Epub 2016 Jan 7.

PMID:
26772427
8.

Optimization of controlled release nanoparticle formulation of verapamil hydrochloride using artificial neural networks with genetic algorithm and response surface methodology.

Li Y, Abbaspour MR, Grootendorst PV, Rauth AM, Wu XY.

Eur J Pharm Biopharm. 2015 Aug;94:170-9. doi: 10.1016/j.ejpb.2015.04.028. Epub 2015 May 16.

PMID:
25986587
9.

Manganese oxide and docetaxel co-loaded fluorescent polymer nanoparticles for dual modal imaging and chemotherapy of breast cancer.

Abbasi AZ, Prasad P, Cai P, He C, Foltz WD, Amini MA, Gordijo CR, Rauth AM, Wu XY.

J Control Release. 2015 Jul 10;209:186-96. doi: 10.1016/j.jconrel.2015.04.020. Epub 2015 Apr 20.

PMID:
25908171
10.

Optimizing the design and in vitro evaluation of bioreactive glucose oxidase-microspheres for enhanced cytotoxicity against multidrug resistant breast cancer cells.

Cheng J, Liu Q, Shuhendler AJ, Rauth AM, Wu XY.

Colloids Surf B Biointerfaces. 2015 Jun 1;130:164-72. doi: 10.1016/j.colsurfb.2015.04.002. Epub 2015 Apr 8.

PMID:
25896537
11.

RGD-conjugated solid lipid nanoparticles inhibit adhesion and invasion of αvβ3 integrin-overexpressing breast cancer cells.

Shan D, Li J, Cai P, Prasad P, Liu F, Rauth AM, Wu XY.

Drug Deliv Transl Res. 2015 Feb;5(1):15-26. doi: 10.1007/s13346-014-0210-2.

PMID:
25787336
12.

A multifunctional polymeric nanotheranostic system delivers doxorubicin and imaging agents across the blood-brain barrier targeting brain metastases of breast cancer.

Li J, Cai P, Shalviri A, Henderson JT, He C, Foltz WD, Prasad P, Brodersen PM, Chen Y, DaCosta R, Rauth AM, Wu XY.

ACS Nano. 2014 Oct 28;8(10):9925-40. doi: 10.1021/nn501069c. Epub 2014 Oct 13.

PMID:
25307677
13.

Synergistic nanoparticulate drug combination overcomes multidrug resistance, increases efficacy, and reduces cardiotoxicity in a nonimmunocompromised breast tumor model.

Shuhendler AJ, Prasad P, Zhang RX, Amini MA, Sun M, Liu PP, Bristow RG, Rauth AM, Wu XY.

Mol Pharm. 2014 Aug 4;11(8):2659-74. doi: 10.1021/mp500093c. Epub 2014 Jun 3.

PMID:
24830351
14.

Multifunctional albumin-MnO₂ nanoparticles modulate solid tumor microenvironment by attenuating hypoxia, acidosis, vascular endothelial growth factor and enhance radiation response.

Prasad P, Gordijo CR, Abbasi AZ, Maeda A, Ip A, Rauth AM, DaCosta RS, Wu XY.

ACS Nano. 2014 Apr 22;8(4):3202-12. doi: 10.1021/nn405773r. Epub 2014 Apr 4. Erratum in: ACS Nano. 2014 Jun 24;8(6):6510.

PMID:
24702320
15.

Matrigel alters the pathophysiology of orthotopic human breast adenocarcinoma xenografts with implications for nanomedicine evaluation.

Shuhendler AJ, Prasad P, Cai P, Hui KK, Henderson JT, Rauth AM, Wu XY.

Nanomedicine. 2013 Aug;9(6):795-805. doi: 10.1016/j.nano.2013.01.005. Epub 2013 Feb 19.

PMID:
23434679
16.

Multifunctional terpolymeric MRI contrast agent with superior signal enhancement in blood and tumor.

Shalviri A, Foltz WD, Cai P, Rauth AM, Wu XY.

J Control Release. 2013 Apr 10;167(1):11-20. doi: 10.1016/j.jconrel.2013.01.014. Epub 2013 Jan 23.

PMID:
23353806
17.

Evaluation of new bi-functional terpolymeric nanoparticles for simultaneous in vivo optical imaging and chemotherapy of breast cancer.

Shalviri A, Cai P, Rauth AM, Henderson JT, Wu XY.

Drug Deliv Transl Res. 2012 Dec;2(6):437-53. doi: 10.1007/s13346-012-0103-1.

PMID:
25787324
18.

A novel solid lipid nanoparticle formulation for active targeting to tumor α(v) β(3) integrin receptors reveals cyclic RGD as a double-edged sword.

Shuhendler AJ, Prasad P, Leung M, Rauth AM, Dacosta RS, Wu XY.

Adv Healthc Mater. 2012 Sep;1(5):600-8. doi: 10.1002/adhm.201200006. Epub 2012 Jul 25.

PMID:
23184795
19.

Special issue on radiation effects on stem cells and non-targeted effects of radiation.

Hill RP, Rauth AM.

Int J Radiat Biol. 2012 Oct;88(10):667. No abstract available.

PMID:
23016737
20.

pH-Dependent doxorubicin release from terpolymer of starch, polymethacrylic acid and polysorbate 80 nanoparticles for overcoming multi-drug resistance in human breast cancer cells.

Shalviri A, Raval G, Prasad P, Chan C, Liu Q, Heerklotz H, Rauth AM, Wu XY.

Eur J Pharm Biopharm. 2012 Nov;82(3):587-97. doi: 10.1016/j.ejpb.2012.09.001. Epub 2012 Sep 17.

PMID:
22995704
21.

Doxorubicin and mitomycin C co-loaded polymer-lipid hybrid nanoparticles inhibit growth of sensitive and multidrug resistant human mammary tumor xenografts.

Prasad P, Shuhendler A, Cai P, Rauth AM, Wu XY.

Cancer Lett. 2013 Jul 1;334(2):263-73. doi: 10.1016/j.canlet.2012.08.008. Epub 2012 Aug 15.

PMID:
22902994
22.

A novel nanoparticle formulation overcomes multiple types of membrane efflux pumps in human breast cancer cells.

Prasad P, Cheng J, Shuhendler A, Rauth AM, Wu XY.

Drug Deliv Transl Res. 2012 Apr;2(2):95-105. doi: 10.1007/s13346-011-0051-1.

PMID:
25786718
23.

Thermally-triggered 'off-on-off' response of gadolinium-hydrogel-lipid hybrid nanoparticles defines a customizable temperature window for non-invasive magnetic resonance imaging thermometry.

Shuhendler AJ, Staruch R, Oakden W, Gordijo CR, Rauth AM, Stanisz GJ, Chopra R, Wu XY.

J Control Release. 2012 Feb 10;157(3):478-84. doi: 10.1016/j.jconrel.2011.09.061. Epub 2011 Sep 10.

PMID:
21939700
24.

Retraction. Relative biological effectiveness (RBE) of fast neutrons in trabecular bone architecture in mice.

Hill RP, Rauth AM, Heinink AT.

Int J Radiat Biol. 2011 Dec;87(12):1210. doi: 10.3109/09553002.2011.611212. Epub 2011 Sep 19. No abstract available.

PMID:
21823819
25.

Hybrid quantum dot-fatty ester stealth nanoparticles: toward clinically relevant in vivo optical imaging of deep tissue.

Shuhendler AJ, Prasad P, Chan HK, Gordijo CR, Soroushian B, Kolios M, Yu K, O'Brien PJ, Rauth AM, Wu XY.

ACS Nano. 2011 Mar 22;5(3):1958-66. doi: 10.1021/nn103024b. Epub 2011 Feb 21.

PMID:
21338075
26.

Characterization of a microsphere formulation containing glucose oxidase and its in vivo efficacy in a murine solid tumor model.

Liu Q, Rauth AM, Liu J, Babakhanian K, Wang X, Bendayan R, Wu XY.

Pharm Res. 2009 Oct;26(10):2343-57. doi: 10.1007/s11095-009-9951-x. Epub 2009 Aug 15.

PMID:
19685212
27.

Cytotoxicity and mechanism of action of a new ROS-generating microsphere formulation for circumventing multidrug resistance in breast cancer cells.

Liu Q, Shuhendler A, Cheng J, Rauth AM, O'Brien P, Wu XY.

Breast Cancer Res Treat. 2010 Jun;121(2):323-33. doi: 10.1007/s10549-009-0473-3. Epub 2009 Jul 18.

PMID:
19618264
28.

A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells.

Shuhendler AJ, Cheung RY, Manias J, Connor A, Rauth AM, Wu XY.

Breast Cancer Res Treat. 2010 Jan;119(2):255-69. doi: 10.1007/s10549-008-0271-3. Epub 2009 Feb 17.

PMID:
19221875
29.

On the synergistic effect of doxorubicin and mitomycin C against breast cancer cells.

Shuhendler AJ, O'Brien PJ, Rauth AM, Wu XY.

Drug Metabol Drug Interact. 2007;22(4):201-33.

PMID:
18447000
30.

Molecular interactions, internal structure and drug release kinetics of rationally developed polymer-lipid hybrid nanoparticles.

Li Y, Wong HL, Shuhendler AJ, Rauth AM, Wu XY.

J Control Release. 2008 May 22;128(1):60-70. doi: 10.1016/j.jconrel.2008.02.014. Epub 2008 Mar 5.

PMID:
18406489
31.

Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles.

Wong HL, Bendayan R, Rauth AM, Li Y, Wu XY.

Adv Drug Deliv Rev. 2007 Jul 10;59(6):491-504. Epub 2007 May 1. Review.

PMID:
17532091
33.

In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model.

Wong HL, Rauth AM, Bendayan R, Wu XY.

Eur J Pharm Biopharm. 2007 Mar;65(3):300-8. Epub 2006 Nov 7.

PMID:
17156986
34.
36.

A new polymer-lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells.

Wong HL, Rauth AM, Bendayan R, Manias JL, Ramaswamy M, Liu Z, Erhan SZ, Wu XY.

Pharm Res. 2006 Jul;23(7):1574-85. Epub 2006 Jun 24.

PMID:
16786442
37.

A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system.

Wong HL, Bendayan R, Rauth AM, Xue HY, Babakhanian K, Wu XY.

J Pharmacol Exp Ther. 2006 Jun;317(3):1372-81. Epub 2006 Mar 17.

PMID:
16547167
38.

In vitro toxicity to breast cancer cells of microsphere-delivered mitomycin C and its combination with doxorubicin.

Cheung RY, Rauth AM, Ronaldson PT, Bendayan R, Wu XY.

Eur J Pharm Biopharm. 2006 Apr;62(3):321-31. Epub 2005 Dec 5.

PMID:
16330194
39.

Biodegradable dextran-based microspheres for delivery of anticancer drug mitomycin C.

Cheung RY, Ying Y, Rauth AM, Marcon N, Yu Wu X.

Biomaterials. 2005 Sep;26(26):5375-85.

PMID:
15814136
40.
41.
42.

A new approach to the in vivo and in vitro investigation of drug release from locoregionally delivered microspheres.

Cheung RY, Kuba R, Rauth AM, Wu XY.

J Control Release. 2004 Nov 5;100(1):121-33.

PMID:
15491816
43.

Development of solid lipid nanoparticles containing ionically complexed chemotherapeutic drugs and chemosensitizers.

Wong HL, Bendayan R, Rauth AM, Wu XY.

J Pharm Sci. 2004 Aug;93(8):1993-2008.

PMID:
15236449
44.

Delivery of an anticancer drug and a chemosensitizer to murine breast sarcoma by intratumoral injection of sulfopropyl dextran microspheres.

Liu Z, Ballinger JR, Rauth AM, Bendayan R, Wu XY.

J Pharm Pharmacol. 2003 Aug;55(8):1063-73.

PMID:
12956895
45.

Accumulation of technetium-99m glucarate: in vitro cell cultures and in vivo tumour models.

Ballinger JR, Hsue V, Rauth AM.

Nucl Med Commun. 2003 May;24(5):597-606.

PMID:
12717079
46.

Flux through multicellular layers of a technetium-99m-nitroimidazole for imaging hypoxia.

Melo T, Tunggal JK, Ballinger JR, Rauth AM.

Cancer Biother Radiopharm. 2002 Oct;17(5):515-26.

PMID:
12470421
47.
48.

A study of doxorubicin loading onto and release from sulfopropyl dextran ion-exchange microspheres.

Liu Z, Cheung R, Wu XY, Ballinger JR, Bendayan R, Rauth AM.

J Control Release. 2001 Dec 13;77(3):213-24.

PMID:
11733089
49.

Cellular accumulation and retention of the technetium-99m-labelled hypoxia markers BRU59-21 and butylene amine oxime.

Zhang X, Melo T, Rauth AM, Ballinger JR.

Nucl Med Biol. 2001 Nov;28(8):949-57.

PMID:
11711315
50.

Comparison of the accumulation and efflux kinetics of technetium-99m sestamibi and technetium-99m tetrofosmin in an MRP-expressing tumour cell line.

Utsunomiya K, Ballinger JR, Piquette-Miller M, Rauth AM, Tang W, Su ZF, Ichise M.

Eur J Nucl Med. 2000 Dec;27(12):1786-92.

PMID:
11189941

Supplemental Content

Loading ...
Support Center